Streptomyces sp. SL-4 which had been isolated and taxonomically characterized during our earlier studies showed promising antibacterial activities. The current study focusses on the extraction, identification and structural elucidation of potential drug molecules present in the extract from SL-4. Characterization of crude preparations from SL-4 revealed that this species is a source of molecules having a broad range of medicinal applications. An extract from this species was subjected to Gas Chromatography-Mass Spectrometry (GC-MS) analysis, which resulted in the detection of volatile compounds. Hexadecane, nonadecane, hexadecanoic acid, and eicosane were identified as most abundant. These are reported for antimicrobial, antioxidant, anti-HIV, antimalarial, antitumor, immunostimulant, and chemopreventive bioactivities. Minor volatile compounds were heneicosane, octadecanoic acid, tetradecane, hexadecanal, heptadecanal, decane, and methyltetracosane. They are reported for antiasthmatics, antimicrobial, anticancer, hepatoprotective, anti-inflammatory, antituberculosis, anti-oxidant, and free radical scavenging activity. Non-volatile compounds were detected by Liquid Chromatography-Mass Spectrometry (LC-MS). Their mass fragmentation patterns confirmed structure; six bioactive compounds were detected, at molecular ion peak m/z 311 the molecule was identified as K-252-C-aglycone indolocarbazole-alkaloid compound. Peak m/z 211 was identified as compound orciprenaline. Peak m/z 453 corresponded to K-252 b, folate-fitc at m/z 872 and m/z 916 was characterized as tylosin. Another compound, leucomycinA1 was detected at molecular ion peak m/z 786. Detected non-volatile compounds are reported for having wide range of bioactivities and medicinal applications. Current study analysed both volatile and non-volatile metabolites of SL-4 and suggested that these compounds can be utilized in pharmaceutical industries for drug development.